🇺🇸 FDA
Patent

US 6685949

Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans

expired A61KA61K2039/5555A61K2039/55572

Quick answer

US patent 6685949 (Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jan 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Feb 03 2004 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/5555, A61K2039/55572, A61K2039/6037, A61K39/1045